X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    development of new antibiotics

    EMA guidance supports development of new antibiotics

    Thermo Fisher Scientific Announces Collaboration with Northeastern University to Advance Biopharmaceutical Characterization and Monitoring Workflows

    Commercial Success In New Biopharmaceutical Innovation Era

    Proteros and AstraZeneca Boost Collaboration Agreement

    Conver to wp

    AbbVie and Cugene Join Forces Concerning Autoimmune Disorders and Cancer

    Drug Imagent For Therapeutic Platform

    Japan Pharma Lobby Says-Price Scheme Is Causing Drug Lag

    Charles River and Valence Discovery Announce Strategic Partnership to Provide Clients with AI-Enabled Drug Design Capabilities

    Charles River and Valo Launch Logica, an Integrated AI-Powered Drug Discovery Solution to Rapidly Deliver Optimized Preclinical Assets

    AstraZeneca announces phase IV ASCENT trial of Tudorza Pressair in patients with COPD meets primary efficacy endpoint

    AstraZeneca announces plans for new strategic R&D centre and Alexion headquarters in Cambridge, Massachusetts

    Lynparza approved in the EU for BRCA-mutated metastatic pancreatic cancer

    Major Success Factors For Clinical Development Organizations

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    development of new antibiotics

    EMA guidance supports development of new antibiotics

    Thermo Fisher Scientific Announces Collaboration with Northeastern University to Advance Biopharmaceutical Characterization and Monitoring Workflows

    Commercial Success In New Biopharmaceutical Innovation Era

    Proteros and AstraZeneca Boost Collaboration Agreement

    Conver to wp

    AbbVie and Cugene Join Forces Concerning Autoimmune Disorders and Cancer

    Drug Imagent For Therapeutic Platform

    Japan Pharma Lobby Says-Price Scheme Is Causing Drug Lag

    Charles River and Valence Discovery Announce Strategic Partnership to Provide Clients with AI-Enabled Drug Design Capabilities

    Charles River and Valo Launch Logica, an Integrated AI-Powered Drug Discovery Solution to Rapidly Deliver Optimized Preclinical Assets

    AstraZeneca announces phase IV ASCENT trial of Tudorza Pressair in patients with COPD meets primary efficacy endpoint

    AstraZeneca announces plans for new strategic R&D centre and Alexion headquarters in Cambridge, Massachusetts

    Lynparza approved in the EU for BRCA-mutated metastatic pancreatic cancer

    Major Success Factors For Clinical Development Organizations

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Manufacturing

Third Rock Ventures $1 Billion Fund To Aid Biotech Startups

Content Team by Content Team
21st June 2022
in Manufacturing, Middle East and South Asia, News
Third Rock Ventures $1 Billion Fund To Aid Biotech Startups

Third Rock Ventures, a well-known funder of biotech startups, announced the closure of a billion-dollar fund recently that would be used to create and grow new life sciences businesses.

The fund, Third Rock’s sixth, is introduced in the midst of a substantial drop in the biotech stock market, raising concerns about venture firms’ capacity to raise new funding and earn returns on their investments. Indeed, the two primary ways early biotech investors generate returns, through initial public offerings and acquisitions, have suffered reductions over the last year or so.

Despite the market downturn, some venture capital firms have raised record amounts for additional life sciences investments. In March this year, Atlas Ventures, which has backed companies such as Actelion and Alnylam Pharmaceuticals, announced the closing of its largest-ever biotech fund, totaling $450 million. Three months later, the Third Rock team has followed suit with a $1.1 billion fund that will support the formation of roughly ten startups.

The last few months have been a challenging time, said Jeffrey Tong, one of Third Rock’s partners. However, on the side of company formation, they simply have a very core following of limited partners who are investing over a long time horizon. Third Rock, which was founded in 2007, claims to have raised nearly $4 billion and invested in more than 60 companies. The company has a three-year fundraising cycle, having previously raised $770mn in 2019, $616mn in 2016, and $516mn in 2013. Each cycle’s goal has been to help around ten startups.

According to partner and chief operating officer at Third Rock, Kevin Gillis, the latest fund was raised between March and May after the company formally chose to continue it last fall. The biotech stock market had only recently begun to fall after reaching new highs when the COVID-19 pandemic drew attention to healthcare. However, in the months since, the decline has become much more pronounced. Since November, the XBI, a well-known biotech stock index, has lost more than half of its value. Fearing that new funding will be tough to come by, many smaller pharma companies are turning to cost-cutting measures.

Larger market patterns and concerns do come up in meetings with limited partners, according to Tong. Third Rock and its investors, on the other hand, are unconcerned, he added, because the firm’s investments are often held for a longer period of time.

For that purpose, Gillis observed that the sixth fund included nearly all of the firm’s core limited partners and some new ones. These cycles have happened previously, Tong added. Over the previous few years, they have had a really good cycle. But, as is typical of the biotech industry, there are multiyear booms followed by dry spells. And they develop businesses to withstand both scenarios.

Third Rock was created in 2008, just before another severe downturn in the biotech markets. The opportunity for nascent biotechs to go public, referred to as the IPO window, was nearly non-existent at the time. They entered the fall of 2008 in a really terrible financial situation, Gillis explained. However, there was a demand for the types of firms that they were establishing, he added. They believe the limited partners see today’s environment as an equally favourable moment to deploy additional capital.

Nonetheless, the tough funding climate is influencing Third Rock’s investment strategy to some extent. Tong explained that the firm is now looking to establish businesses that are a little bit more grown up at the time of launch. According to Tong, such businesses would be on schedule to get a lead medication programme into human testing in two years from launch, as opposed to some past Third Rock investments, which took four to five years.

Third Rock’s new fund will give the Series A funding that biotech businesses generally disclose when they launch, as well as follow-on funding to help them grow. Additionally, part of the new funds will be used to fund companies founded by the firm’s fifth fund. Third Rock, like Flagship Pioneering, which established Moderna and a slew of other biotechs, has shifted its focus to autonomously fostering businesses over the years.

Third Rock has been doing a bit more syndication with its fifth fund, and now into its sixth, allowing other venture companies to invest early in its enterprises. According to Tong, the move was made in the hopes that the market would eventually correct itself after the recent surge, and that recurrence would make certain companies a little more resilient. According to Tong, Third Rock has set aside a “little sleeve” of funds for “developing enterprises” outside the firm.

Previous Post

Alzheimers Disease Can Be Diagnosed By A Single Brain Scan

Next Post

Australia Grants $143.3mn To Sydney Biomedical Accelerator

Related Posts

FDA Experts Recommend Changing COVID Jab Formulation In Fall
Manufacturing

FDA Experts Recommend Changing COVID Jab Formulation In Fall

30th June 2022
Novartis to acquire The Medicines Company for USD 9.7 bn
Manufacturing

Novartis To Slash 8,000 Jobs To Save $1 Billion By 2024

30th June 2022
How Lag In African COVID-19 Jabs Slowed Its Once Rapid Pace
Manufacturing

How Lag In African COVID-19 Jabs Slowed Its Once Rapid Pace

27th June 2022
Australia Creates A Novel Stem Cell Production Technique
Manufacturing

Australia Creates A Novel Stem Cell Production Technique

27th June 2022
Novartis to acquire The Medicines Company for USD 9.7 bn
Manufacturing

Novartis Promises $250M For Tropical Illnesses, Malaria

27th June 2022
GSK commences phase III study of Benlysta and rituximab combination in systemic lupus erythematosus
Manufacturing

GSK Commits £1 Billion To Combat Infections In Poor Nations

27th June 2022
Next Post
Takara Bio and Boston IVF Fertility Center Announce Partnership to Enable the Derivation of Clinical-grade hES cell lines for Cell Therapy Applications

Australia Grants $143.3mn To Sydney Biomedical Accelerator

Latest News

FDA Experts Recommend Changing COVID Jab Formulation In Fall
Manufacturing

FDA Experts Recommend Changing COVID Jab Formulation In Fall

30th June 2022
Novartis to acquire The Medicines Company for USD 9.7 bn
Manufacturing

Novartis To Slash 8,000 Jobs To Save $1 Billion By 2024

30th June 2022
How Lag In African COVID-19 Jabs Slowed Its Once Rapid Pace
Manufacturing

How Lag In African COVID-19 Jabs Slowed Its Once Rapid Pace

27th June 2022
Australia Creates A Novel Stem Cell Production Technique
Manufacturing

Australia Creates A Novel Stem Cell Production Technique

27th June 2022
Novartis to acquire The Medicines Company for USD 9.7 bn
Manufacturing

Novartis Promises $250M For Tropical Illnesses, Malaria

27th June 2022
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In